A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients

Carcinogenesis

Volumn 29, Issue 9, 2008, Pages 1758-1764

  Woelfelschneider, Andreas ^a   Popanda, Odilia ^a   Lilla, Carmen ^a   Linseisen, Jakob ^a   Mayer, Claudia ^a   Celebi, Oktay ^b   Debus, Jürgen ^b   Bartsch, Helmut ^a   Chang Claude, Jenny ^a   Schmezer, Peter ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CAROTENE; CANTHAXANTHIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GENOMIC DNA; MESSENGER RNA; PROTEIN MDM2; PROTEIN P53; XANTHOPHYLL;

ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DNA REPAIR; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; LIFESTYLE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; TREATMENT RESPONSE;

AGED; ALCOHOL DRINKING; BETA CAROTENE; BODY MASS INDEX; CANTHAXANTHIN; DNA-BINDING PROTEINS; ENDONUCLEASES; HAPLOTYPES; HUMANS; LUTEIN; LYMPHOCYTES; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SMOKING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 51849143661     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn067     Document Type: Article

References (51)

1. Mader,R.M. (2006) Links between biology, prognosis and prediction of response to chemotherapy in colorectal cancer. Onkologie, 29 334-341.
2. Burczynski,M.E. et al. (2005) Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin. Cancer Res., 11, 1181-1189.
3. Bartsch,H. et al. (2007) Genetic risk profiles for cancer susceptibility and therapy response. Recent Results Cancer Res., 174, 19-36.
4. Efferth,T. et al. (2005) Pharmacogenetics for individualized cancer chemotherapy. Pharmacol. Ther., 107, 155-176.
5. Gu,J. et al. (2005) Roles of tumor suppressor and telomere maintenance genes in cancer and aging-an epidemiological study. Carcinogenesis, 26, 1741-1747.
6. Vogel,U. et al. (2006) ERCC1, XPD and RAI mRNA levels in lymphocytes are not associated with lung cancer risk in a prospective study of Danes. Mutat. Res., 593, 88-96.
7. Cheng,L. et al. (2002) Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer, 94, 393-397.
8. Chalabi,N. et al. (2004) The effects of lycopene on the proliferation of human breast cells and BRCA1 and BRCA2 gene expression. Eur. J. Cancer, 40, 1768-1775.
9. Bustin,S.A. et al. (2004) Pitfalls of quantitative real-time reverse- transcription polymerase chain reaction. J. Biomol. Tech. 15, 155-166.
10. Suk,R. et al. (2005) Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin. Cancer Res. 11, 1534-1538.
11. Chen,P. et al. (2000) Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol. Biomarkers Prev., 9, 843-847.
12. Isla,D. et al. (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol., 15, 1194-1203.
13. Reed,E. (2005) ERCC1 and clinical resistance to platinum-based therapy. Clin. Cancer Res., 11, 6100-6102.
14. Ryuj.J.S. et al. (2004) Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer, 44, 311-316.
15. Yu,J.J. et al. (2000) Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int. J. Oncol., 16 555-560.
16. Ohmiya,N. et al. (2006) MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J. Clin. Oncol., 24, 4434-4440.
17. Bond,G.L. et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602.
18. Tan,X.L. et al. (2006) Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. Breast Cancer Res. Treat., 97, 225-262.
19. Gemignani,F. et al. (2004) A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene, 23, 1954-1956.
20. Chomczynski,P. et al. (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162, 156-159.
21. Pfaffl,M.W. (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res., 29, e45.
22. Yin,J. et al. (2002) Rapid genotyping of human ERCC1 exon 4 polymorphism with fluorescence analysis using fluorophore-labeled hybridization probes and a lightcycler. Biochem. Genet., 40, 143-148.
23. Zhou,W. et al. (2004) Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res., 10, 4939-4943.
24. Sotamaa,K. et al. (2005) p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin. Cancer Res., 11, 6840-6844.
25. Hess,D. et al. (1991) Simultaneous determination of retinol, tocopherols, carotenes and lycopene in plasma by means of high-performance liquid chromatography on reversed phase. Int. J. Vitam. Nutr. Res., 61, 232-238.
26. Comstock,G.W. et al. (1993) Reported effects of long-term freezer storage on concentrations of retinol, beta-carotene, and alpha-tocopherol in serum or plasma summarized. Clin. Chem., 39 1075-1077.
27. Speitling,A. et al. (1992) Methodenhandbuch der Verbundstudie Ernährungserhebung und Risikofaktoren Analytik. Wissenschaftlicher Fachverlag Dr. Fleck, Niederkleen, Germany.
28. Xie,X. et al. (1993) Testing linkage disequlibrium between a disease gene and marker loci. Am. J. Hum. Genet., 53 (suppl): 313.
29. Stephens,M. et al. (2003) A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet., 73, 1162-1169.
30. Pine,S.R. et al. (2006) MDM2, SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol. Biomarkers Prev., 15 1559-1561.
31. Yang,M. et al. (2006) Effects of ERCC 1 expression in peripheral blood on the risk of head and neck cancer. Eur. J. Cancer Prev., 15, 269-273.
32. Park,D.J. et al. (2002) ERCC1 polymorphism is associated with differential ERCC1 mRNA levels. Proc. AACR 2002, 321.
33. Reed,E. (1998) Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat. Rev., 24 331-344.
34. Warnecke-Eberz,U. et al. (2004) High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin. Cancer Res., 10 3794-3799.
35. Hurteau,G.J. et al. (2002) mRNA-specific reverse transcription-polymerase chain reaction from human tissue extracts. Anal. Biochem., 307, 304-315.
36. Ovstebo,R. et al. (2003) PCR-based calibration curves for studies of quantitative gene expression in human monocytes: Development and evaluation. Clin. Chem., 49, 425-432.
37. Stahlberg,A. et al. (2004) Properties of the reverse transcription reaction in mRNA quantification. Clin. Chem., 50, 509-515.
38. Bustin,S.A. et al. (2005) Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis. Clin. Sci. (Lond), 109, 365-379.
39. Almeida,A. et al. (2004) Gene expression analysis by real-time reverse transcription polymerase chain reaction: Influence of tissue handling. Anal. Biochem., 328, 101-108.
40. Lapillonne,H. et al. (2006) High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J. Clin. Oncol., 24, 1507-1515.
41. Radonic,A. et al. (2005) Reference gene selection for quantitative real-time PCR analysis in virus infected cells: SARS corona virus, Yellow fever virus, Human Herpesvirus-6, Camelpox virus and cytomegalovirus infections. Virol. J., 2, 7.
42. Cheng,L. et al. (2000) Reduced expression levels of nucleotide excision repair genes in lung cancer: A case-control analysis. Carcinogenesis, 21, 1527-1530.
43. Hanis,S.L. et al. (2005) The p53 pathway: Positive and negative feedback loops. Oncogene, 24, 2899-2908.
44. MollerP. et al. (2004) Interventions with antioxidants and nutrients in relation to oxidative DNA damage and repair. Mutat. Res. 551, 79-89.
45. Moller,P. et al. (2003) No effect of 600 grams fruit and vegetables per day on oxidative DNA damage and repair in healthy nonsmokers. Cancer Epidemiol. Biomarkers Prev., 12, 1016-1022.
46. Astley,S.B. et al. (2004) Evidence that dietary supplementation with carotenoids and carotenoid-rich foods modulates the DNA damage: repair balance in human lymphocytes. Br. J. Nutr., 91, 63-72.
47. Chen,L. et al. (2001) Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J. Natl Cancer Inst., 93, 1872-1879.
48. Dakubo,G.D. et al. (2006) Altered metabolism and mitochondrial genome in prostate cancer. J. Clin. Pathol., 59, 10-16.
49. El Zein,R. et al. (2005) Chromosomal instability in peripheral blood lymphocytes and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev., 14, 748-752.
50. Stacewicz-Sapuntzakis,M. et al. (2005) Role of lycopene and tomato products in prostate health. Biochim. Biophys. Acta, 1740, 202-205.
51. Vogel,U. et al. (2000) DNA repair capacity: Inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat. Res., 461, 197-210.